CYTK
A little profit-taking, anyone?
Cytokinetics’ Executive Vice President and Chief Commercial Officer, Andrew Callos, sold 7,449 shares of common stock on April 15 for $66.02 a pop, totaling $491,782. After the sale, he still held 58,555 shares directly.
Why investors care
Insider selling can sometimes feel like a smoke alarm, but context matters. This happened near Cytokinetics’ 52-week high, after the stock had already ripped 72% over the past year — so this looks a lot like someone taking some chips off the table after a very nice run.
The bigger backdrop
The sale also comes as the company has been getting a fairly bullish chorus from Wall Street:
- Mizuho lifted its price target to $100, citing an extended IP runway for aficamten through 2041 and a 75% probability of success for the asset
- JPMorgan raised its target to $75 and kept an Overweight rating, pointing to the market’s positive reaction to Myqorzo’s approval for obstructive hypertrophic cardiomyopathy
Big picture: one insider sale doesn’t change the thesis by itself, but after a big rally, it can remind you that even the folks inside the house like to lock in gains sometimes.